Ransom Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ransom Advisory’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4	Closed	-$974	–	324
2025 Q1	$974	Hold	4	–	–	﹤0.01%	317
2024 Q4	$1.31K	Hold	4	–	–	﹤0.01%	388
2024 Q3	$1.34K	Sell	4 -75	-95%	-$23.8K	﹤0.01%	388
2024 Q2	$21.6K	Buy	+79	New	+$23K	0.01%	289

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Ransom Advisory's BIO Position: Q2 2025 in Review

Ransom Advisory sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 4 shares — an estimated $974 sold.

Ransom Advisory first reported a position in BIO in Q2 2024 and held it in 4 quarters. The position peaked at $21.6K in Q2 2024. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Ransom Advisory reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Ransom Advisory sold 4 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $974.
Ransom Advisory first reported a position in Bio-Rad Laboratories Class A in Q2 2024 and held it in 4 quarters.
Ransom Advisory's Bio-Rad Laboratories Class A position peaked at $21.6K in Q2 2024.
384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Ransom Advisory's 13F filing for Q2 2025, filed 8 Jul 2025.